Skip navigation
Merrion pharmaceuticals - making medicines better
HomeLink
Skip navigation

Regulatory News

03 February 2016

Directorate Change

Merrion Pharmaceuticals plc today announces the resignation of Harry Stratford, Senior Independent Non-Executive Director and Gerard Flood, Non-Executive Director from the Board of Directors of Merrion with effect from 31 January 2016. The resignations are in line with Merrion's strategy following the completion of the transactions involving Novo Nordisk A/S in December 2015 (as set out in the circular posted to shareholders on 27 November 2015).

Michael McKenna, Merrion's Chairman, said 'the Board is very appreciative of the significant contribution that Harry and Gerard have each made to the Company, particularly in the past year, and we wish them well for the future. I and the remaining directors, John Fox and Fintan Maher, will continue to serve as directors of the Company to pursue the investing policy as approved by our shareholders in December 2015'.

 

For further information contact:

Company
Merrion Pharmaceuticals plc
Dr. John Fox, CEO
+353 1 469 3719
Financial Adviser/ESM Adviser
Davy Corporate Finance
Anthony Farrell / Patrick Bance
+ 353 1 679 6363
Media Enquiries
Dempsey Corporate
Conor Dempsey
+353 86 247 9892
conor.dempsey@dempseycorporate.com

 

<< Back to Regulatory News